The Cardiovascular Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the cardiovascular partnering deals and agreements entered into by the worlds leading healthcare companies

Recent market research analysis by Current Agreements shows that partnering in the last decade has seen an increase in cardiovascular deals with an increase in modern diagnostic technology development.

Partnering deal analysis in the last decade has seen an increase in cardiovascular partnering with an increase in modern diagnostic technologies

The collaboration focuses on developing microRNA-based therapeutics for cardiovascular and muscle disease

Aspen Pharma, a global branded and generics pharmaceutical manufacturer, has found a place in the top 50 big pharma companies listed by Current Partnering.

Aspen Pharmacare specialises in the production of branded and generic pharmaceuticals and is currently the biggest pharmaceutical company in South Africa taking a 15% share of the total market.

Big pharma company Bayer , is going hunting for pharma deals again, with its chief executive expected to tell media outlets  that it is looking for further takeover pharma deals. 

The field of regenerative medicine is an up and coming new approach of targeting and treating diseases, it involves the repair and restoration of previously damaged tissues or organs in the body. The regenerative medicine market was worth $16bn in 2013 and industry analysts predict that this will leap to over $60bn by 2020. The more »

This month we provide you with an overview of deal analysis in the life science sectors, covering partnering, M&A and financing in September 2014.

The partnering and M&A  trends and deal analysis of the top 50 pharma and biotech companies reveals a flurry of data that is interesting to observe for efficient deal making.

The bioinformatics partnering deal trend analysis 2009 to 2014 are reviewed in this article.

X-Chem has licensed a second drug discovery program to Bayer Pharma pursuant to the multi-target collaboration the companies established in July 2012

Cardiovascular Systems announced an upcoming IPO worth up to $70 million in net proceeds.

Amgen and Servier have terminated pharma deals involving the cardiovascular drug Procoralan.

Amgen and Servier announced new pharma deals leveraging each company’s commitment to cardiovascular disease.

AstraZeneca and Karolinska Institutet enter pharma deals to establish a unique integrated cardiovascular and metabolic research centre as part of a $100 million joint venture.

Athera Biotechnologies has entered into pharma deals involving an option agreement with Boehringer Ingelheim on a novel preclinical antibody program.

AstraZeneca, a big pharma company has ventured in a pharma partnering pact with Fundan Univ.

Abbott and St. Jude Medical announced Choice Alliance, a multi-year joint pharma alliances initiative that provides mutual U.S. customers access to a robust portfolio of interventional cardiology, cardiac rhythm management, electrophysiology and intravascular imaging and diagnostic technologies

Bristol-Myers Squibb and Simcere have announced that the companies have expanded the strategic partnership formed last year to include a second collaboration in a different therapeutic area. 

The collaborative preclinical research projects will focus on identifying disease mechanisms and biological targets that have the potential to be starting points for successful and commercially viable treatments of these diseases, both major causes of cardiovascular morbidity and mortality worldwide. The financial terms of the deal were not disclosed.